Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and warrants, raising $5 million in gross proceeds, with potential additional funds from warrant exercises totaling up to $10 million.
Use of Proceeds: The company plans to utilize the net proceeds for clinical trials, patent portfolio maintenance, and general corporate purposes, while also highlighting its focus on regenerative medicine for bone through strategic partnerships.
Trade with 70% Backtested Accuracy
Analyst Views on BBLGW
No data
About the author
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
Bone Biologics Files Patent Application for Bone Regeneration Technology
Patent Application Filed: Bone Biologics Corporation has filed a patent application for its novel NELL-1 protein, aimed at treating bone conditions, which could enhance its intellectual property portfolio and support clinical development efforts.
Company Overview: Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is collaborating with strategic partners to advance the research and development of its products.